Identification and Optimization of Inhibitors of Trypanosomal Cysteine Proteases: Cruzain, Rhodesain, and TbCatB

被引:103
作者
Mott, Bryan T. [1 ]
Ferreira, Rafaela S. [2 ,4 ,5 ]
Simeonov, Anton [1 ]
Jadhav, Ajit [1 ]
Ang, Kenny Kean-Hooi [3 ]
Leister, William [1 ]
Shen, Min [1 ]
Silveira, Julia T. [1 ]
Doyle, Patricia S. [5 ]
Arkin, Michelle R. [3 ]
McKerrow, James H. [5 ]
Inglese, James [1 ]
Austin, Christopher P. [1 ]
Thomas, Craig J. [1 ]
Shoichet, Brian K. [2 ]
Maloney, David J. [1 ]
机构
[1] NHGRI, NIH, Chem Genom Ctr, Bethesda, MD 20892 USA
[2] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA
[3] Univ Calif San Francisco, Small Mol Discovery Ctr, San Francisco, CA 94158 USA
[4] Univ Calif San Francisco, Grad Program Chem & Chem Biol, San Francisco, CA 94158 USA
[5] Univ Calif San Francisco, Sandler Ctr Basic Res Parasit Dis, San Francisco, CA 94158 USA
基金
美国国家卫生研究院;
关键词
CHAGAS-DISEASE; CATHEPSIN-B; MOUSE MODEL; INFECTION; POTENT; MECHANISM; LIBRARIES; BRUCEI;
D O I
10.1021/jm901069a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Trypanosoma cruzi and Trypanosoma brucei are parasites that cause Chagas' disease and African sleeping sickness, respectively. Both parasites rely oil essential cysteine proteases for survival: cruzain for T. cruzi and TbCatB/rhodesain for T. brucei. A recent quantitative high-throughput screen of cruzain identified triazine nitriles. which are known inhibitors of other cysteine proteases, its reversible inhibitors of the enzyme. Structural modifications detailed herein, including core scaffold modification from triazine to purine, improved the in vitro potency against both cruzain and rhodesain by 350-fold, while also gaining activity against T. brucei parasites. Selected compounds were screened against it panel of human cysteine and serine proteases to determine selectivity, and it cocrystal was obtained of our most potent analogue bound to cruzain.
引用
收藏
页码:52 / 60
页数:9
相关论文
共 33 条
[1]   RNA Interference of Trypanosoma brucei Cathepsin B and L Affects Disease Progression in a Mouse Model [J].
Abdulla, Maha-Hamadien ;
O'Brien, Theresa ;
Mackey, Zachary B. ;
Sajid, Mohamed ;
Grab, Dennis J. ;
McKerrow, James H. .
PLOS NEGLECTED TROPICAL DISEASES, 2008, 2 (09)
[2]   Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K [J].
Altmann, E ;
Cowan-Jacob, SW ;
Missbach, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (24) :5833-5836
[3]  
[Anonymous], 2002, PYMOL MOL GRAPHICS S
[4]   NIH Molecular Libraries Initiative [J].
Austin, CP ;
Brady, LS ;
Insel, TR ;
Collins, FS .
SCIENCE, 2004, 306 (5699) :1138-1139
[5]  
BAILEY A, 2006, Patent No. 7125881
[6]   Regioselective N-9 arylation of purines employing arylboronic acids in the presence of Cu(II) [J].
Bakkestuen, AK ;
Gundersen, LL .
TETRAHEDRON LETTERS, 2003, 44 (16) :3359-3362
[7]   A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi [J].
Barr, SC ;
Warner, KL ;
Kornreic, BG ;
Piscitelli, J ;
Wolfe, A ;
Benet, L ;
McKerrow, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) :5160-5161
[8]  
BHATT R, 2003, Patent No. 200303037346
[9]   Identification of a new class of nonpeptidic inhibitors of cruzain [J].
Brak, Katrien ;
Doyle, Patricia S. ;
McKerrow, James H. ;
Ellman, Jonathan A. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (20) :6404-6410
[10]   A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection [J].
Doyle, Patricia S. ;
Zhou, Yuan M. ;
Engel, Juan C. ;
McKerrow, James H. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (11) :3932-3939